Shattuck Labs (Shattuck Labs) FCF Margin % : -1,449.42% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Shattuck Labs's Free Cash Flow for the three months ended in Mar. 2024 was $-16.16 Mil. Shattuck Labs's Revenue for the three months ended in Mar. 2024 was $1.12 Mil. Therefore, Shattuck Labs's FCF Margin % for the quarter that ended in Mar. 2024 was -1,449.42%.

As of today, Shattuck Labs's current FCF Yield % is -20.31%.

The historical rank and industry rank for Shattuck Labs's FCF Margin % or its related term are showing as below:

STTK' s FCF Margin % Range Over the Past 10 Years
Min: -16274.85 Med: -281.52 Max: -36.01
Current: -2624.68

During the past 6 years, the highest FCF Margin % of Shattuck Labs was -36.01%. The lowest was -16274.85%. And the median was -281.52%.

STTK's FCF Margin % is ranked worse than
84.2% of 1044 companies
in the Biotechnology industry
Industry Median: -141.025 vs STTK: -2624.68

Shattuck Labs FCF Margin % Historical Data

The historical data trend for Shattuck Labs's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs FCF Margin % Chart

Shattuck Labs Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-216.90

-346.14

-216.68

-16,274.85

-4,926.67

Shattuck Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-46,554.39	-9,456.00	-2,441.84	-2,722.13	-1,449.42

Competitive Comparison of Shattuck Labs's FCF Margin %

For the Biotechnology subindustry, Shattuck Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shattuck Labs's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shattuck Labs's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Shattuck Labs's FCF Margin % falls into.

Shattuck Labs FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Shattuck Labs's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-81.635	/	1.657
	=	-4,926.67 %

Shattuck Labs's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-16.161	/	1.115
	=	-1,449.42 %

Shattuck Labs FCF Margin % Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shattuck Labs (Shattuck Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701

Website

https://www.shattucklabs.com

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Executives

Andrew R Neill	officer: See Remarks	1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
Stephen Stout	officer: See Remarks	C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla	officer: Chief Technical Officer	500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein	director	500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson	officer: General Counsel	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower	director, 10 percent owner, officer: Chairman	3317 BOWMAN AVE, AUSTIN TX 78703
Taylor Schreiber	director, officer: Chief Executive Officer	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Tyler Brous	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung	officer: Chief Business Officer	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Arundathy N. Pandite	officer: Chief Medical Officer	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703